CD274 and non-small cell lung carcinoma: An analysis of CTCs in advanced NSCLC patients receiving nivolumab treatment revealed that the presence of CTCs or the expression of PD-L1 on the surface of CTCs could reflect treatment efficacy: patients with PD-L1+ CTCs were more likely to experience disease progression.